CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE
Background:
Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.
Methods and Findings:
Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive plasma viral load measurements <50 copies/µl and ending with either a measurement >500 copies/µl, the first of two consecutive measurements between 50–500 copies/µl, cART interruption or administrative censoring. We used stratified multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median 2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/µl (95% CI) of: 0.35 (0.30–0.40) for counts <200 cells/µl, 0.81 (0.71–0.92) for counts 200 to <350 cells/µl, 0.74 (0.66–0.83) for counts 350 to <500 cells/µl, and 0.96 (0.92–0.99) for counts ≥500 cells/µl. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts <200 cells/µl.
Conclusions:
Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell count <200 cells/µl but still some slight benefit for those with a CD4 cell count ≥500 cells/µl.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Med 9(3): e32767. doi:10.1371/journal.pmed.1001194
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001194
Souhrn
Background:
Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.
Methods and Findings:
Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive plasma viral load measurements <50 copies/µl and ending with either a measurement >500 copies/µl, the first of two consecutive measurements between 50–500 copies/µl, cART interruption or administrative censoring. We used stratified multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median 2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/µl (95% CI) of: 0.35 (0.30–0.40) for counts <200 cells/µl, 0.81 (0.71–0.92) for counts 200 to <350 cells/µl, 0.74 (0.66–0.83) for counts 350 to <500 cells/µl, and 0.96 (0.92–0.99) for counts ≥500 cells/µl. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts <200 cells/µl.
Conclusions:
Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell count <200 cells/µl but still some slight benefit for those with a CD4 cell count ≥500 cells/µl.
: Please see later in the article for the Editors' Summary
Zdroje
1. MayMTSterneJACostagliolaDSabinCAPhillipsAN 2006 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368 451 458
2. VoTTLedergerberBKeiserOHirschelBFurrerH 2008 Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 197 1685 1694
3. EggerMMayMCheneGPhillipsANLedergerberB 2002 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 119 129
4. CheneGSterneJAMayMCostagliolaDLedergerberB 2003 Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362 679 686
5. Panel on Antiretroviral Guidelines for Adults and Adolescents 2011 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 17 October 2011
6. TherneauTM 1996 Extending the Cox model. Mayo Clinic, Rochester, Minnesota, Department of Health Science Research. Available: http://mayoresearch.mayo.edu/mayo/research/biostat/techreports.cfm. Accessed 22 August 2011
7. CastroKGWardJWSlutskerLBuehlerJWJaffeHW 1992 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults Department of Health and Human Services Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed 12 November 2011
8. GreenlandS 1995 Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6 356 365
9. GliddenDVVittinghoffE 2004 Modelling clustered survival data from multicentre clinical trials. Stat Med 23 369 388
10. AltmanDGDe StavolaBL 1994 Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13 301 341
11. HessKR 1995 Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14 1707 1723
12. BelleraCAMacGroganGDebledMde LaraCTBrousteV 2010 Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 10 20
13. SabinCASmithCJd'ArminioMABattegayMGabianoC 2008 Response to combination antiretroviral therapy: variation by age. AIDS 22 1463 1473
14. LodwickRCostagliolaDReissPTortiCTeiraR 2010 Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 170 410 419
15. PutterHFioccoMGeskusRB 2007 Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26 2389 2430
16. SnapinnSMJiangQIglewiczB 2005 Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. American Statistician 59 301 307
17. DouekDCRoedererMKoupRA 2009 Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60 471 484
18. EstesJDHaaseATSchackerTW 2008 The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol 20 181 186
19. LedergerberBLundgrenJDWalkerASSabinCJusticeA 2004 Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364 51 62
20. KaufmannGRElziLWeberRFurrerHGiulieriS 2011 Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 25 441 451
21. PhillipsANLundgrenJD 2006 The CD4 lymphocyte count and risk of clinical progression. Curr Opin HIV AIDS 1 43 49
22. HoggRSYipBChanKJWoodECraibKJ 2001 Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286 2568 2577
23. BycottPTaylorJ 1998 A comparison of smoothing techniques for CD4 data measured with error in a time-dependent Cox proportional hazards model. Stat Med 17 2061 2077
24. AndersenPKLiestolK 2003 Attenuation caused by infrequently updated covariates in survival analysis. Biostatistics 4 633 649
25. HernanMAHernandez-DiazSWerlerMMMitchellAA 2002 Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 155 176 184
26. PhillipsAPezzottiP 2004 Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 18 51 58
27. MocroftALedergerberBZilmerKKirkOHirschelB 2007 Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 21 1867 1875
28. Antiretroviral Therapy Cohort Collaboration 2010 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50 1387 1396
29. SterneJAMayMCostagliolaDde WolfFPhillipsAN 2009 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373 1352 1363
30. KitahataMMGangeSJAbrahamAGMerrimanBSaagMS 2009 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360 1815 1826
31. WolbersMBattegayMHirschelBFurrerHCavassiniM 2007 CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 12 889 897
32. GreubGLedergerberBBattegayMGrobPPerrinL 2000 Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356 1800 1805
33. PotterMOdueyungboAYangHSaeedSKleinMB 2010 Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 24 1857 1865
34. JusticeAC 2010 Commentary: Treated HIV infection is a chronic disease: the case against cause of death analyses. Int J Epidemiol 39 146 148
35. SmithCSabinCALundgrenJDThiebautRWeberR 2010 Factors associated with specific causes of death amongst HIV-positive individuals in the D∶A∶D Study. AIDS 24 1537 1548
36. LoutfyMRGenebatMMooreDRaboudJChanK 2010 A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 55 451 459
37. KelleyCFKitchenCMHuntPWRodriguezBHechtFM 2009 Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48 787 794
38. AbramsDLevyYLossoMHBabikerACollinsG 2009 Interleukin-2 therapy in patients with HIV infection. N Engl J Med 361 1548 1559
39. HatanoHHayesTLDahlVSinclairELeeTH 2011 A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 203 960 968
40. KeiserOAnastosKSchechterMBalestreEMyerL 2008 Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13 870 879
41. BartlettJAShaoJF 2009 Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 9 637 649
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2012 Číslo 3
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
Najčítanejšie v tomto čísle
- Guidance for Evidence-Informed Policies about Health Systems: Assessing How Much Confidence to Place in the Research Evidence
- Uterine Rupture by Intended Mode of Delivery in the UK: A National Case-Control Study
- Guidance for Evidence-Informed Policies about Health Systems: Linking Guidance Development to Policy Development
- Improving Ethical Review of Research Involving Incentives for Health Promotion